Review



c36950 mouse cxcl13 blc bca 1 quantikine elisa r d systems  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    R&D Systems c36950 mouse cxcl13 blc bca 1 quantikine elisa r d systems
    C36950 Mouse Cxcl13 Blc Bca 1 Quantikine Elisa R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 43 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/c36950 mouse cxcl13 blc bca 1 quantikine elisa r d systems/product/R&D Systems
    Average 93 stars, based on 43 article reviews
    c36950 mouse cxcl13 blc bca 1 quantikine elisa r d systems - by Bioz Stars, 2026-03
    93/100 stars

    Images



    Similar Products

    mouse cxcl13/blc/bca-1 antibody  (Bio-Techne corporation)
    99
    Bio-Techne corporation mouse cxcl13/blc/bca-1 antibody
    Mouse Cxcl13/Blc/Bca 1 Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse cxcl13/blc/bca-1 antibody/product/Bio-Techne corporation
    Average 99 stars, based on 1 article reviews
    mouse cxcl13/blc/bca-1 antibody - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier
    recombinant murine cxcl13  (MedChemExpress)
    92
    MedChemExpress recombinant murine cxcl13
    Recombinant Murine Cxcl13, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant murine cxcl13/product/MedChemExpress
    Average 92 stars, based on 1 article reviews
    recombinant murine cxcl13 - by Bioz Stars, 2026-03
    92/100 stars
    		  Buy from Supplier
    recombinant mouse cxcl13  (PeproTech)
    90
    PeproTech recombinant mouse cxcl13
    FVIII TRuCε CXCR5 Tregs display improved in vitro and in vivo persistence. (A) In vitro migration of FVIII CAR, FVIII CAR CXCR5, and FVIII TRuCε transduced Tregs through a transwell in response to either serum free media, <t>CXCL12</t> or CXCL13 gradients. Number of migrated mScarlet + cells at the bottom of the transwell are quantified by flow cytometry following 6hrs of incubation. (B) Kinetics of in vivo migration of adoptively transferred FVIII TRuCε or FVIII TRuCε CXCR5 T conv cells to the spleen on days 1, 2, 4, and 7 following adoptive transfer. Mice received i.v. injections of recombinant FVIII on days 0, 3, and 6. Frequencies of mScarlet + cells per total CD4 + T cells are quantified by flow cytometry. (C) Number of mScarlet + FVIII TRuCε or FVIII TRuCε CXCR5 Tregs per 10 7 CD4 + T cells are quantified from spleens and (D) inguinal lymph nodes (ILN) on day 7 post adoptive transfer. Data represents mean±SEM, ****p<0.0001, ∗p < 0.05, ∗∗p < 0.01 using 2-way ANOVA with Tukey’s multiple comparisons analysis for (A) , 2-way ANOVA with Sidak’s multiple comparisons analysis for (B) , unpaired t test for (C, D) .
    Recombinant Mouse Cxcl13, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant mouse cxcl13/product/PeproTech
    Average 90 stars, based on 1 article reviews
    recombinant mouse cxcl13 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    hy p77912  (MedChemExpress)
    90
    MedChemExpress hy p77912
    FVIII TRuCε CXCR5 Tregs display improved in vitro and in vivo persistence. (A) In vitro migration of FVIII CAR, FVIII CAR CXCR5, and FVIII TRuCε transduced Tregs through a transwell in response to either serum free media, <t>CXCL12</t> or CXCL13 gradients. Number of migrated mScarlet + cells at the bottom of the transwell are quantified by flow cytometry following 6hrs of incubation. (B) Kinetics of in vivo migration of adoptively transferred FVIII TRuCε or FVIII TRuCε CXCR5 T conv cells to the spleen on days 1, 2, 4, and 7 following adoptive transfer. Mice received i.v. injections of recombinant FVIII on days 0, 3, and 6. Frequencies of mScarlet + cells per total CD4 + T cells are quantified by flow cytometry. (C) Number of mScarlet + FVIII TRuCε or FVIII TRuCε CXCR5 Tregs per 10 7 CD4 + T cells are quantified from spleens and (D) inguinal lymph nodes (ILN) on day 7 post adoptive transfer. Data represents mean±SEM, ****p<0.0001, ∗p < 0.05, ∗∗p < 0.01 using 2-way ANOVA with Tukey’s multiple comparisons analysis for (A) , 2-way ANOVA with Sidak’s multiple comparisons analysis for (B) , unpaired t test for (C, D) .
    Hy P77912, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hy p77912/product/MedChemExpress
    Average 90 stars, based on 1 article reviews
    hy p77912 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    c36950 mouse cxcl13 blc bca 1 quantikine elisa r d systems  (R&D Systems)
    93
    R&D Systems c36950 mouse cxcl13 blc bca 1 quantikine elisa r d systems
    FVIII TRuCε CXCR5 Tregs display improved in vitro and in vivo persistence. (A) In vitro migration of FVIII CAR, FVIII CAR CXCR5, and FVIII TRuCε transduced Tregs through a transwell in response to either serum free media, <t>CXCL12</t> or CXCL13 gradients. Number of migrated mScarlet + cells at the bottom of the transwell are quantified by flow cytometry following 6hrs of incubation. (B) Kinetics of in vivo migration of adoptively transferred FVIII TRuCε or FVIII TRuCε CXCR5 T conv cells to the spleen on days 1, 2, 4, and 7 following adoptive transfer. Mice received i.v. injections of recombinant FVIII on days 0, 3, and 6. Frequencies of mScarlet + cells per total CD4 + T cells are quantified by flow cytometry. (C) Number of mScarlet + FVIII TRuCε or FVIII TRuCε CXCR5 Tregs per 10 7 CD4 + T cells are quantified from spleens and (D) inguinal lymph nodes (ILN) on day 7 post adoptive transfer. Data represents mean±SEM, ****p<0.0001, ∗p < 0.05, ∗∗p < 0.01 using 2-way ANOVA with Tukey’s multiple comparisons analysis for (A) , 2-way ANOVA with Sidak’s multiple comparisons analysis for (B) , unpaired t test for (C, D) .
    C36950 Mouse Cxcl13 Blc Bca 1 Quantikine Elisa R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/c36950 mouse cxcl13 blc bca 1 quantikine elisa r d systems/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    c36950 mouse cxcl13 blc bca 1 quantikine elisa r d systems - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    mouse cxcl13 forward 50 catagatcggattcaagttacgcc  (OriGene)
    99
    OriGene mouse cxcl13 forward 50 catagatcggattcaagttacgcc
    FVIII TRuCε CXCR5 Tregs display improved in vitro and in vivo persistence. (A) In vitro migration of FVIII CAR, FVIII CAR CXCR5, and FVIII TRuCε transduced Tregs through a transwell in response to either serum free media, <t>CXCL12</t> or CXCL13 gradients. Number of migrated mScarlet + cells at the bottom of the transwell are quantified by flow cytometry following 6hrs of incubation. (B) Kinetics of in vivo migration of adoptively transferred FVIII TRuCε or FVIII TRuCε CXCR5 T conv cells to the spleen on days 1, 2, 4, and 7 following adoptive transfer. Mice received i.v. injections of recombinant FVIII on days 0, 3, and 6. Frequencies of mScarlet + cells per total CD4 + T cells are quantified by flow cytometry. (C) Number of mScarlet + FVIII TRuCε or FVIII TRuCε CXCR5 Tregs per 10 7 CD4 + T cells are quantified from spleens and (D) inguinal lymph nodes (ILN) on day 7 post adoptive transfer. Data represents mean±SEM, ****p<0.0001, ∗p < 0.05, ∗∗p < 0.01 using 2-way ANOVA with Tukey’s multiple comparisons analysis for (A) , 2-way ANOVA with Sidak’s multiple comparisons analysis for (B) , unpaired t test for (C, D) .
    Mouse Cxcl13 Forward 50 Catagatcggattcaagttacgcc, supplied by OriGene, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse cxcl13 forward 50 catagatcggattcaagttacgcc/product/OriGene
    Average 99 stars, based on 1 article reviews
    mouse cxcl13 forward 50 catagatcggattcaagttacgcc - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier
    anti-mouse cxcl13 apc  (Thermo Fisher)
    90
    Thermo Fisher anti-mouse cxcl13 apc
    FVIII TRuCε CXCR5 Tregs display improved in vitro and in vivo persistence. (A) In vitro migration of FVIII CAR, FVIII CAR CXCR5, and FVIII TRuCε transduced Tregs through a transwell in response to either serum free media, <t>CXCL12</t> or CXCL13 gradients. Number of migrated mScarlet + cells at the bottom of the transwell are quantified by flow cytometry following 6hrs of incubation. (B) Kinetics of in vivo migration of adoptively transferred FVIII TRuCε or FVIII TRuCε CXCR5 T conv cells to the spleen on days 1, 2, 4, and 7 following adoptive transfer. Mice received i.v. injections of recombinant FVIII on days 0, 3, and 6. Frequencies of mScarlet + cells per total CD4 + T cells are quantified by flow cytometry. (C) Number of mScarlet + FVIII TRuCε or FVIII TRuCε CXCR5 Tregs per 10 7 CD4 + T cells are quantified from spleens and (D) inguinal lymph nodes (ILN) on day 7 post adoptive transfer. Data represents mean±SEM, ****p<0.0001, ∗p < 0.05, ∗∗p < 0.01 using 2-way ANOVA with Tukey’s multiple comparisons analysis for (A) , 2-way ANOVA with Sidak’s multiple comparisons analysis for (B) , unpaired t test for (C, D) .
    Anti Mouse Cxcl13 Apc, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-mouse cxcl13 apc/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    anti-mouse cxcl13 apc - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    anti-mouse cxcl13-apc  (Thermo Fisher)
    90
    Thermo Fisher anti-mouse cxcl13-apc
    FVIII TRuCε CXCR5 Tregs display improved in vitro and in vivo persistence. (A) In vitro migration of FVIII CAR, FVIII CAR CXCR5, and FVIII TRuCε transduced Tregs through a transwell in response to either serum free media, <t>CXCL12</t> or CXCL13 gradients. Number of migrated mScarlet + cells at the bottom of the transwell are quantified by flow cytometry following 6hrs of incubation. (B) Kinetics of in vivo migration of adoptively transferred FVIII TRuCε or FVIII TRuCε CXCR5 T conv cells to the spleen on days 1, 2, 4, and 7 following adoptive transfer. Mice received i.v. injections of recombinant FVIII on days 0, 3, and 6. Frequencies of mScarlet + cells per total CD4 + T cells are quantified by flow cytometry. (C) Number of mScarlet + FVIII TRuCε or FVIII TRuCε CXCR5 Tregs per 10 7 CD4 + T cells are quantified from spleens and (D) inguinal lymph nodes (ILN) on day 7 post adoptive transfer. Data represents mean±SEM, ****p<0.0001, ∗p < 0.05, ∗∗p < 0.01 using 2-way ANOVA with Tukey’s multiple comparisons analysis for (A) , 2-way ANOVA with Sidak’s multiple comparisons analysis for (B) , unpaired t test for (C, D) .
    Anti Mouse Cxcl13 Apc, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-mouse cxcl13-apc/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    anti-mouse cxcl13-apc - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    rat anti-mouse cxcl13–apc  (Thermo Fisher)
    90
    Thermo Fisher rat anti-mouse cxcl13–apc
    FVIII TRuCε CXCR5 Tregs display improved in vitro and in vivo persistence. (A) In vitro migration of FVIII CAR, FVIII CAR CXCR5, and FVIII TRuCε transduced Tregs through a transwell in response to either serum free media, <t>CXCL12</t> or CXCL13 gradients. Number of migrated mScarlet + cells at the bottom of the transwell are quantified by flow cytometry following 6hrs of incubation. (B) Kinetics of in vivo migration of adoptively transferred FVIII TRuCε or FVIII TRuCε CXCR5 T conv cells to the spleen on days 1, 2, 4, and 7 following adoptive transfer. Mice received i.v. injections of recombinant FVIII on days 0, 3, and 6. Frequencies of mScarlet + cells per total CD4 + T cells are quantified by flow cytometry. (C) Number of mScarlet + FVIII TRuCε or FVIII TRuCε CXCR5 Tregs per 10 7 CD4 + T cells are quantified from spleens and (D) inguinal lymph nodes (ILN) on day 7 post adoptive transfer. Data represents mean±SEM, ****p<0.0001, ∗p < 0.05, ∗∗p < 0.01 using 2-way ANOVA with Tukey’s multiple comparisons analysis for (A) , 2-way ANOVA with Sidak’s multiple comparisons analysis for (B) , unpaired t test for (C, D) .
    Rat Anti Mouse Cxcl13–Apc, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti-mouse cxcl13–apc/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    rat anti-mouse cxcl13–apc - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    FVIII TRuCε CXCR5 Tregs display improved in vitro and in vivo persistence. (A) In vitro migration of FVIII CAR, FVIII CAR CXCR5, and FVIII TRuCε transduced Tregs through a transwell in response to either serum free media, CXCL12 or CXCL13 gradients. Number of migrated mScarlet + cells at the bottom of the transwell are quantified by flow cytometry following 6hrs of incubation. (B) Kinetics of in vivo migration of adoptively transferred FVIII TRuCε or FVIII TRuCε CXCR5 T conv cells to the spleen on days 1, 2, 4, and 7 following adoptive transfer. Mice received i.v. injections of recombinant FVIII on days 0, 3, and 6. Frequencies of mScarlet + cells per total CD4 + T cells are quantified by flow cytometry. (C) Number of mScarlet + FVIII TRuCε or FVIII TRuCε CXCR5 Tregs per 10 7 CD4 + T cells are quantified from spleens and (D) inguinal lymph nodes (ILN) on day 7 post adoptive transfer. Data represents mean±SEM, ****p<0.0001, ∗p < 0.05, ∗∗p < 0.01 using 2-way ANOVA with Tukey’s multiple comparisons analysis for (A) , 2-way ANOVA with Sidak’s multiple comparisons analysis for (B) , unpaired t test for (C, D) .

    Journal: Frontiers in Immunology

    Article Title: CXCR5 engineered human and murine Tregs for targeted suppression in secondary and tertiary lymphoid organs

    doi: 10.3389/fimmu.2025.1513009

    Figure Lengend Snippet: FVIII TRuCε CXCR5 Tregs display improved in vitro and in vivo persistence. (A) In vitro migration of FVIII CAR, FVIII CAR CXCR5, and FVIII TRuCε transduced Tregs through a transwell in response to either serum free media, CXCL12 or CXCL13 gradients. Number of migrated mScarlet + cells at the bottom of the transwell are quantified by flow cytometry following 6hrs of incubation. (B) Kinetics of in vivo migration of adoptively transferred FVIII TRuCε or FVIII TRuCε CXCR5 T conv cells to the spleen on days 1, 2, 4, and 7 following adoptive transfer. Mice received i.v. injections of recombinant FVIII on days 0, 3, and 6. Frequencies of mScarlet + cells per total CD4 + T cells are quantified by flow cytometry. (C) Number of mScarlet + FVIII TRuCε or FVIII TRuCε CXCR5 Tregs per 10 7 CD4 + T cells are quantified from spleens and (D) inguinal lymph nodes (ILN) on day 7 post adoptive transfer. Data represents mean±SEM, ****p<0.0001, ∗p < 0.05, ∗∗p < 0.01 using 2-way ANOVA with Tukey’s multiple comparisons analysis for (A) , 2-way ANOVA with Sidak’s multiple comparisons analysis for (B) , unpaired t test for (C, D) .

    Article Snippet: Lower chambers contained 600 μL serum-free medium with 1μg/mL of either recombinant mouse CXCL12 or CXCL13 (PeproTech, Rocky Hill, NJ).

    Techniques: In Vitro, In Vivo, Migration, Flow Cytometry, Incubation, Adoptive Transfer Assay, Recombinant